Marbofloxacin

• Catalog No.: S1464
• CAS Number: 115550-35-1
• M. F.: C17H19FN4O4
• M. W.: 362.3555632
• Storage: -20°C

SYNONYMS

• IUPAC name: 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
• IUPAC Traditional name: marbofloxacin
• Synonyms: Marbocyl; Zeniquin

DATABASE IDS

• CAS Number: 115550-35-1

PROPERTIES

• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Infection

Biological Activity

• Description: Marbofloxacin is a potent antibiotic inhibiting bacterial DNA replication.
• In Vitro: Marbofloxacin is a fluoroquinolone antimicrobial agent developed exclusively for veterinary use. Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as Mycoplasma spp. As the third generation fluoroquinolone, Marbofloxacin also mainly targets replication and transcription enzymes such as DNA gyrase and topoisomerase IV, which are both essential for bacterial viability. Marbofloxacin has a mycoplasmacidal effect during the exponential phase but not during the lag phase, in both the M. hyopneumoniae 116 wild-type strain and a clone isolated 4 days post-marbofloxacin treatment in vivo at the therapeutic dose. ^[1] Marbofloxacin significantly kills Leishmania promastigotes and intracellular amastigotes in a dose-dependent manner, more efficient than meglumine antimoniate and sodium stibogluconate. After treatment with Marbofloxacin, macrophages acquire resistance to infection and enhanced antileishmanial activity through the NO synthase pathway. ^[2]
• In Vivo: Marbofloxacin treatment at the therapeutic dose does not eliminate M. hyopneumoniae, with 87.5 to 100% of the pigs still positive at the end of the assays, and is not effective in significantly reducing clinical signs. Nevertheless, Marbofloxacin treatment seems to decrease the lung lesion scores. ^[1] Administration of Marbofloxacin at 6 mg/kg once daily for 7 days in a Staphylococcus aureus infection in tissue cages in ponies is not effective for the elimination of S. aureus infections from secluded sites. ^[3]

Protocol

• Protocol: Animal Study ^[1]
• Animal Models: SPF piglets inoculated intratracheally with M. hyopneumoniae strain 116
• Formulation: Dissolved DMSO, and diluted in saline
• Doses: ~2 mg/kg/day
• Administration: Intramuscular injection

References

• References: [1] Le Carrou J, et al. Antimicrob Agents Chemother, 2006, 50(6), 1959-1966.
• References: [2] Vouldoukis I, et al. Vet Parasitol, 2006, 135(2), 137-146.
• References: [3] Voermans M, et al. J Vet Pharmacol Ther, 2006, 29(6), 555-560.